The Japanese drugmaker’s revenue grew to 45.46 billion yen, up from 39.96 billion yen a year earlier. Alongside the top-line growth, operating profit climbed to 5.65 billion yen, compared to 3.64 billion yen in the previous year’s corresponding period. Pretax profit followed a similar trajectory, rising to 5.19 billion yen from 2.66 billion yen.

Reflecting these results, earnings per share rose to 89.82 yen, significantly higher than the 39.42 yen reported in the prior year. The company compiled these figures in accordance with Japanese accounting standards.